Physician profile
Daisy Vo
NPI 1811331226
$15,558.78
in general payments reported to CMS, 2019-2025
28 companies · $4,165 in 2025
The $4,165 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,574 · 2022: $2,154 · 2023: $3,207 · 2024: $3,459 · 2025: $4,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,831.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,624.23 | 2021-2025 | |
| Gilead Sciences, INC. | $2,805.70 | 2021-2025 | |
| Intra-Sana Laboratories | $1,948.89 | 2021-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,212.04 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $804.79 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Redhill Biopharma INC. | $484.49 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Madrigal Pharmaceuticals | $375.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $200.70 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $190.22 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $174.98 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $166.49 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $165.39 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $156.84 | 2021-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $143.81 | 2021-2025 | Eohilia, Entyvio |
| Nestle Healthcare Nutrition INC. | $140.51 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $131.32 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2022 | |
| Merck Sharp & Dohme LLC | $124.67 | 2021-2024 | Dificid |
| Qol Medical, LLC | $121.28 | 2021-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $109.36 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $74.50 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $60.24 | 2024-2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $49.31 | 2021-2023 | Linzess |
| Orphalan INC | $48.63 | 2024-2025 | Cuvrior |
| Ferring Pharmaceuticals INC. | $47.38 | 2021-2022 | |
| Lilly USA, LLC | $44.06 | 2025 | Omvoh |
| Pfizer INC. | $16.07 | 2023 | |
| Braintree Laboratories, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.